Life Technologies Announces SFDA Clearance for its 3500xL Dx Genetic Analyzer in China and the Launch of 10 Assays from its Joint Venture with Daan Gene
SHANGHAI, March 27, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced that its Applied Biosystems 3500xL Dx Genetic Analyzer has been approved by China's State Food and Drug Administration (SFDA) for clinical diagnostic use in China and the launch of 10 Assays from its joint venture with Daan Gene. The development marks a major extension of Life Technologies' capabilities to serve the clinical end market in China with Sanger-based solutions.
The 3500xL Dx is an automated 24 capillary-based Sanger Sequencer designed for a wide range of sequencing applications. It delivers high quality performance, higher throughput and increased productivity for clinical laboratories around the world.
Together with Life Technologies' genetic analyzer 3500 Dx that was approved by SFDA for IVD use in 2011 in China, the 3500 series genetic analyzers are intended for use in a wide range of applications in the process of clinical research, including de novo sequencing and mutational profiling as well as HLA typing. The newly expanded offering of both the 3500 Dx and the 3500xL Dx provides hospitals of all sizes the flexibility they need to meet their unique throughput demands.
Based on the 3500 Dx series platform, ten assays have been developed or licensed by Guangzhou Life Technologies DaAn Diagnostics Co. Ltd, a joint venture that established in 2012 between Life Technologies and Daan Gene Co. Ltd. of Sun Yat Sen University. These assays will be used for genotypic and drug resistance testing, cancer mutation identification and the prenatal chromosome disorder detection. Currently, nine out of the ten assays are Research Use Only kits and the other one that can be used in Trisomy 21 prenatal screening for Down syndrome is SFDA registered. The company is currently conducting clinical trials and is actively seeking the SFDA approval for the remaining nine kits.
"The current approval of the 3500xL Dx by SFDA emphasizes Life Technologies' success in pursuing regulatory pathways for our diagnostics laboratory instruments as well as our vision to becoming a global leader in the molecular diagnostics industry," said Ronnie Andrews, president of Medical Sciences at Life Technologies.
"As in other countries, China is facing the challenges of fighting with infectious diseases like HBV, TB, HCV and HIV, as well as various genetic-based diseases like lung cancer, breast cancer, and ovarian cancers, etc. The early detection and treatment of these diseases will greatly increase the recovery and survival rate of patients," said Dr. Siddhartha Kadia, president of Life Technologies Greater China. "Life Technologies is committed to bring more medical diagnostic products, like the 3500xL Dx genetic analyzer to support clinical research and diagnostics, which are expected to lead to a higher quality of life for Chinese people and more economical healthcare solutions."
Applied Biosystems Sanger Sequencers supplied the technology that powered the Human Genome Project, and Sanger instruments remain the sequencing "gold-standard" for accuracy, reliability and ease of use. The participation of the sequencing technologies in clinical diagnostics is reshaping the disease treatment paradigm worldwide.
Additional products offered by Life Technologies for the molecular diagnostics lab market in China include: the Applied Biosystem 7500, 7500 Fast Dx, StepOne, StepOne Plus, ViiA7 Dx qPCR series. Veriti™ Dx Thermal Cycler is in the process of SFDA registration in China.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact:
Vivian Lv, External Affairs & Corporate Communications
+86 10 8446 1901
SOURCE Life Technologies Corporation